NEW YORK (GenomeWeb News) – KineMed today announced the renewal of its non-exclusive research collaboration with Pfizer.

The deal was originally forged a year ago and seeks to develop new approaches to specific metabolic diseases, in particular type 2 diabetes. Under the agreement, KineMed's dynamic proteomics technology platform will be used to map the impact of potential drug candidates, the Emeryville, Calif.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.